Contact
searchSearch
HMP Global
Login

Genitourinary Cancer Resource Center

Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
Zibelman Headshot
Videos
Exploring the Potential of Nivolumab and Axitinib in Renal Cell Carcinoma
03/11/2025
Matthew Zibelman, MD
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares...
03/11/2025
Journal of Clinical Pathways
Doshi Headshot
Videos
Assessing Real-World Outcomes of First-Line Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma
02/18/2025
Sahil Doshi, MD
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi,...
02/18/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
From Oncology
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Stephanie Holland
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
From Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Stephanie Holland
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
From Oncology

Expert Insights

Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Zibelman Headshot
Videos
Exploring the Potential of Nivolumab and Axitinib in Renal Cell Carcinoma
03/11/2025
Matthew Zibelman, MD
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares results from his study on combination systemic therapy with tyrosine kinase inhibitor nivolumab and immune checkpoint inhibitor axitinib for patients with metastatic renal cell carcinoma.
Matthew Zibelman, MD, shares...
03/11/2025
Journal of Clinical Pathways
Doshi Headshot
Videos
Assessing Real-World Outcomes of First-Line Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma
02/18/2025
Sahil Doshi, MD
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi, MD, discusses the outcomes of a recent trial he authored on first-line ipilimumab and nivolumab for metastatic renal cell carcinoma, highlighting its implications for clinical practice and payer considerations.
In this interview, Sahil Doshi,...
02/18/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Dr Rana McKay.
ENGAGING EXPERTS
Antitumor Activity of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
06/19/2023
Rana McKay, MD
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary medical oncologist at the University of California San Diego, discusses the results of EV-103 cohort K, which assessed the efficacy of enfortumab vedotin monotherapy or in combination with pembrolizumab in...
Dr Rana McKay, a genitourinary...
06/19/2023
Journal of Clinical Pathways
Barragan-Carrillo, MD
Conference Coverage
Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma
06/08/2023
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...
In an interview with the Journal...
06/08/2023
Journal of Clinical Pathways
Dr Jeff Yorio.
Videos
Costs of Adverse Event Management for Patients with Metastatic Renal Cell Carcinoma Treated With a VEGFR TKI
05/25/2023
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology, Austin, TX, discusses the findings from his study that examined the health care costs associated with adverse events in patients with metastatic renal cell carcinoma who have been treated with a VEGFR TKI.
Jeff Yorio, MD, Texas Oncology,...
05/25/2023
Journal of Clinical Pathways
Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways

Newsfeed

News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
Headshot
Videos
The Role of ctDNA Clearance in RCC: Retrospective Analysis and Clinical Implications
02/13/2025
Adanma Ayanambakkam, MD
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma Ayanambakkam, MD, discusses his study on the use of circulating tumor DNA (ctDNA) clearance as a biomarker in renal cell carcinoma (RCC), highlighting findings from a single-institution retrospective study and its...
In this interview, Adanma...
02/13/2025
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Renee Saliby, MD
Videos
Using Intermediate Endpoints to Evaluate the Efficacy of ICIs for Treating Metastatic Renal Cell Carcinoma
03/22/2024

Featuring Renée Saliby, MD

Featuring Renée Saliby, MD
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her study on whether intermediate endpoints are associated with overall survival in patients with renal cell carcinoma receiving ICI-based treatments.
Renée Saliby, MD, summarizes her...
03/22/2024
Journal of Clinical Pathways
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
Amanda Nizam, MD
Videos
The Potential of Enfortumab Vedotin After Maintenance Avelumab For Treating Patients With Advanced Urothelial Carcinoma: The UNITE Study
03/04/2024

Featuring Amanda Nizam, MD

Featuring Amanda Nizam, MD
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the outcomes of using enfortumab vedotin after maintenance avelumab for treating patients with advanced urothelial carcinoma.
Amanda Nizam, MD, discusses the...
03/04/2024
Journal of Clinical Pathways
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Stephanie Holland
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Stephanie Holland
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
News
FDA Approves Belzutifan for Patients With Advanced Renal Cell Carcinoma
01/23/2024
Grace Taylor, MS, MA
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to belzutifan for patients with advanced renal cell carcinoma after they have received a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
The FDA has granted approval to...
01/23/2024
Journal of Clinical Pathways
News
FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer
01/10/2024
Grace Taylor, MS, MA
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
The FDA has granted approval to...
01/10/2024
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
Conference Coverage
Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact
09/10/2025
Grace Taylor, MS, MA
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session,...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Building a Transparent Framework for Predictable Cost of Care in Oncology Pathways
09/10/2025
Hannah Musick
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Reviewing a Decade of Oncology Pathways: Standardization, Gaps, and the Road to Real-Time Intelligence
09/09/2025
Hannah Musick
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
AI as a Thought Partner: Reframing Innovation in Medicine and Practice Management
09/09/2025
Grace Taylor, MS, MA
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx,...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
How AI is Reshaping Clinical Practice, Governance, and Patient Trust
09/09/2025
Grace Taylor, MS, MA
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
From Dispensing to Decision-Making: How Pharmacists Are Redefining Leadership in Oncology Care
09/08/2025
Grace Taylor, MS, MA
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Theranostics: Clinical Promise, Operational Hurdles, and the Road Ahead
09/08/2025
Hannah Musick
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Scaling Bispecifics and CAR T-Cell Therapy in Community Oncology: From Promise to Practice
09/08/2025
Hannah Musick
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Practical Insights for Embedding Whole-Person Care into Clinical Pathways
09/08/2025
Juliet Gallagher
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025...
09/08/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Oral Anticancer Agent Use Among Older Patients With mRCC
09/20/2021
True or False: Oral anticancer agent adherence in patients with metastatic renal cell carcinoma is low, especially for those with multiple comorbidities and high frailty.
True or False: Oral anticancer agent adherence in patients with metastatic renal cell carcinoma is low, especially for those with multiple comorbidities and high frailty.
True or False: Oral anticancer...
09/20/2021
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Expansion and Managing Genitourinary Cancers
07/16/2021
True or False: Medicaid expansion is associated with a decreased uninsured rate, an increased proportion of early-stage diagnosis for kidney and prostate cancers, and an increased proportion of patients receiving active surveillance for...
True or False: Medicaid expansion is associated with a decreased uninsured rate, an increased proportion of early-stage diagnosis for kidney and prostate cancers, and an increased proportion of patients receiving active surveillance for...
True or False: Medicaid...
07/16/2021
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use